Predicting long-term (≥ 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants
| Autor: | Trey Spencer, Athanasios Fassas, Maurizio Zangari, Ashraf Badros, Guido Tricot, Jeffrey R. Sawyer, Bart Barlogie, Raman Desikan, D. Spoon, Amir A. Toor, Elias Anaissie, Nikhil C. Munshi |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Melphalan
medicine.medical_specialty Multivariate analysis business.industry Beta-2 microglobulin Hematology Odds ratio Logistic regression medicine.disease Gastroenterology Surgery Transplantation Internal medicine Medicine business Monoclonal gammopathy of undetermined significance Multiple myeloma medicine.drug |
| Zdroj: | British Journal of Haematology. 116:211-217 |
| ISSN: | 0007-1048 |
| DOI: | 10.1046/j.1365-2141.2002.03231.x |
| Popis: | Summary. Although outcome in multiple myeloma (MM) patients has improved significantly with the introduction of autotransplants (AT), the curability of this approach remained to be demonstrated. Therefore, we analysed outcome and prognostic factors using a logistic regression model in 515 consecutive newly diagnosed and previously treated patients intended to receive melphalan-based tandem transplants with follow up of ‡ 5 years. One quarter of patients had event-free survivals (EFS) ‡ 5 years with no further relapses seen after 7 years (46 patients on plateau). On multivariate analysis, factors associated with EFS ‡ 5 years were absence of chromosome 11 and 13 abnormalities (odds ratio: 6AE1), £ 12 months of preceding standard-dose therapy (SDT) (OR: 2AE6) and b-2 microglobulin (B2M) level £ 2AE5 mg/l at time of first AT (OR: 1AE7). Patients with only favourable variables (25%) had a 7-year EFS in excess of 35%, compared with 15% and 10%, respectively, with one (43%) or two unfavourable variables (27%), and 0% for 5% of patients with three unfavourable variables (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text